Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.

Mar 13, 2025 - 23:23
 0
Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.